Stock Market Reviews

KALV (KalVista Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on KALV (KalVista Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
  FRAMINGHAM, Mass. & SALISBURY, England, December 22, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE approved in Japan.
  Dec 22, 2025 - $KALV
• Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
  PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
  Dec 4, 2025 - $KALV
• Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment
  Pharvaris stock surged Wednesday — and KalVista reversed higher — on promising test results for an HAE treatment.
  Dec 3, 2025 - $KALV
• Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects
  Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) is one of the best breakout stocks to invest in. On November 11, analysts at Citizens lowered their price target of the stock to $28 from $29 while reiterating a Market Perform rating. Despite the cut, the price target remains well above the current trading range, indicating significant upside potential. The […]
  Nov 18, 2025 - $KALV
• Ekterly Momentum Shows Royalty Asset Value For DRI Healthcare Trust, Says Stifel Canada
  Kalvista Pharmaceutical's drug Ekterly (sebetralstat) is off to a strong start since its July launch
  Nov 12, 2025 - $KALV
• KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ...
  KalVista Pharmaceuticals Inc (KALV) reports robust demand for EKTERLY, financial resilience, and strategic international expansion amid ongoing payer negotiations.
  Nov 11, 2025 - $KALV
• KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
  FRAMINGHAM, Mass. & SALISBURY, England, November 10, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025.
  Nov 10, 2025 - $KALV
• KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
  FRAMINGHAM, Mass. & SALISBURY, England, November 06, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), as well as physician and patient survey and consensus study data highlighting the substantial unmet need for safe, effective and easy-to-use on-demand treatments, presented at the American College of All
  Nov 6, 2025 - $KALV
• KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
  FRAMINGHAM, Mass. & SALISBURY, England, November 05, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences:
  Nov 5, 2025 - $KALV
• KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
  FRAMINGHAM, Mass. & SALISBURY, England, November 03, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company’s third quarter financial results and provide an operational update.
  Nov 3, 2025 - $KALV